Myovant fiscal year
WebJul 28, 2024 · Myovant 2024 fiscal year is off to a strong start, marked by significant volume driven growth for both ORGOVYX and MYFEMBREE and with regulatory advances that enable us to reach more patients ... WebMay 11, 2024 · As we close out our fiscal year, Myovant recorded $231 million of total revenue, including net product revenues of $94.3 million. Of that, $32.4 million of net product revenues were recorded...
Myovant fiscal year
Did you know?
WebOct 26, 2024 · Second fiscal quarter 2024 total revenues of $77.9 million; net product revenue from U.S. sales of ORGOVYX® of $18.7 million and MYFEMBREE® of $0.6 millionEstimated 8,000 cumulative ... WebJan 26, 2024 · Myovant Sciences, Inc. Third fiscal quarter 2024 total revenue of $100.2 million; including net product revenue of $61.4 million Net product revenue from U.S. …
WebMyovant Sciences Announces Financial Results for Second Quarter of Fiscal Year 2024 and Corporate Updates October 26, 2024 Second fiscal quarter 2024 total revenues of $77.9 … WebApr 26, 2024 · BASEL, Switzerland, April 26, 2024 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) today announced it will host a webcast and conference call to discuss …
WebMar 31, 2024 · Fiscal year 2024 total revenue of $231.0 million , including net product revenues of $94.3 million ; fourth fiscal quarter 2024 total revenues of $57.6 million , … WebOct 26, 2024 · Second fiscal quarter 2024 total revenues of $77.9 million; net product revenue from U.S. sales of ORGOVYX ® of $18.7 million and MYFEMBREE ® of $0.6 million
WebSecond fiscal quarter 2024 total revenue of $104.8 million; including net product revenue of $49.9 million; Net product revenue from U.S. sales of ORGOVYX ® of $43.3 million in …
WebMyovant Sciences Announces Preliminary Financial Results for Third Quarter of Fiscal Year 2024 January 10, 2024 Estimated total revenue of $54.0-$55.0 million , including net … troy-bilt tb30r parts diagramWebOct 19, 2024 · A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as … troy-bilt tb30r reviewsWebAug 5, 2024 · Myovant to host conference call and webcast on Monday, August 8, 2024, at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time; ... A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, ... troy-bilt tb490bc manualtroy-bilt tb4hb ecWebApr 26, 2024 · BASEL, Switzerland, April 26, 2024 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) today announced it will host a webcast and conference call to discuss corporate updates and financial results... troy-bilt tb475ss partsWebApr 13, 2024 · Myovant Sciences has a 1-year low of $7.67 and a 1-year high of $27.06. The company has a market capitalization of $2.62 billion, a P/E ratio of -14.13 and a beta of 2.17. ... On average, research analysts expect that Myovant Sciences will post -1.82 earnings per share for the current fiscal year. Insiders Place Their Bets. troy-bilt tb30r vs craftsmanWebOct 26, 2024 · BASEL, Switzerland, Oct. 26, 2024 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, … troy-bilt tb330 lawn mower